Last reviewed · How we verify
Genasense followed by DTIC; then DTIC alone
Genasense followed by DTIC; then DTIC alone is a Small molecule drug developed by Genta Incorporated. It is currently in Phase 1 development.
At a glance
| Generic name | Genasense followed by DTIC; then DTIC alone |
|---|---|
| Sponsor | Genta Incorporated |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Genasense followed by DTIC; then DTIC alone CI brief — competitive landscape report
- Genasense followed by DTIC; then DTIC alone updates RSS · CI watch RSS
- Genta Incorporated portfolio CI
Frequently asked questions about Genasense followed by DTIC; then DTIC alone
What is Genasense followed by DTIC; then DTIC alone?
Genasense followed by DTIC; then DTIC alone is a Small molecule drug developed by Genta Incorporated.
Who makes Genasense followed by DTIC; then DTIC alone?
Genasense followed by DTIC; then DTIC alone is developed by Genta Incorporated (see full Genta Incorporated pipeline at /company/genta-incorporated).
What development phase is Genasense followed by DTIC; then DTIC alone in?
Genasense followed by DTIC; then DTIC alone is in Phase 1.